<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03119233</url>
  </required_header>
  <id_info>
    <org_study_id>STP 203</org_study_id>
    <nct_id>NCT03119233</nct_id>
  </id_info>
  <brief_title>The DETOUR2 Clinical Study</brief_title>
  <official_title>The Detour Endovascular Technique for Long OcclUsive Fem-pop Revascularization - 2 Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PQ Bypass, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PQ Bypass, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, single-arm, multi-center, international clinical investigation to evaluate the&#xD;
      safety and effectiveness of the PQ Bypass System to access, deliver guidewires, and implant&#xD;
      stent grafts for a percutaneous femoropopliteal (fem-pop) bypass.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The DETOUR2 study is a prospective, single-arm, multi-center, international, non-randomized,&#xD;
      safety and effectiveness clinical investigation of the PQ Bypass system.&#xD;
&#xD;
      The PQ Bypass System is intended to improve blood flow in patients with symptomatic&#xD;
      peripheral arterial disease due to symptomatic femoropopliteal chronic total occlusions ≥ 20&#xD;
      cm (TASC D) that can include de novo, restenotic, or in-stent restenotic lesions; or&#xD;
      Symptomatic femoropopliteal lesions ≥ 24 cm (total lesion length) that can include a chronic&#xD;
      total occlusion or a ≥70% lesion that includes de novo, restenotic or in-stent restenosis&#xD;
      (complex TASC C), with reference vessel diameters ranging from 5.0 - 6.7 mm, by investigator&#xD;
      visual assessment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 13, 2017</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Effectiveness Endpoint</measure>
    <time_frame>12 months</time_frame>
    <description>The absence of clinically-driven target lesion revascularization and/or absence of recurrent target lesion diameter stenosis &gt;50% by imaging (e.g., duplex ultrasound (peak systolic velocity ratio of &gt;2.5) or invasive angiography) with the stent or immediately 1 cm above or below the treated segment.). When both modalities are available, angiography takes precedence.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Safety Endpoint</measure>
    <time_frame>30 days</time_frame>
    <description>Freedom from a major adverse event (MAE) at 30 days post-procedure defined as any occurrence of the following events: Death, Clinically-Driven Target Lesion Revascularization (CD-TLR), Major Amputation of(above the Treated Limb,ankle), Symptomatic Deep Vein Thrombosis (DVT), Pulmonary Embolism, or procedure-related bleeding requiring any transfusion of packed red blood cells or surgery.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">202</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>Single-Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The PQ Bypass system is used during a minimally invasive procedure to place stent grafts in the peripheral vasculature to improve blood flow.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PQ Bypass System</intervention_name>
    <description>Intended use from CLN114 Rev F (CLN114 is the DETOUR2 protocol) The PQ Bypass System is intended to improve blood flow in patients with peripheral arterial disease in symptomatic femoropopliteal lesions due to chronic total occlusions ≥ 20 cm (TASC D) that can include de novo, restenotic, or in-stent restenotic lesions; or total lesion lengths ≥24 cm that can include chronic total occlusions or a ≥70% lesion that includes de novo, restenotic or in-stent restenosis (complex TASC C).</description>
    <arm_group_label>Single-Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        All subjects are required to meet the following inclusion criteria in order to be&#xD;
        considered eligible for participation in the study:&#xD;
&#xD;
        General Inclusion Criteria&#xD;
&#xD;
          1. Age &gt; 18 and ≤ 90 years of age.&#xD;
&#xD;
          2. Willing and able to provide informed consent.&#xD;
&#xD;
          3. Subject is willing to undergo all follow-up assessments according to the specified&#xD;
             schedule over 36 months.&#xD;
&#xD;
             Clinical Inclusion Criteria&#xD;
&#xD;
          4. Chronic, symptomatic lower limb ischemia defined as Rutherford clinical categories 3,&#xD;
             4, or 5.&#xD;
&#xD;
          5. Venous Clinical Severity Score &lt; 3.&#xD;
&#xD;
          6. Subject is a suitable candidate for angiography and endovascular intervention and, if&#xD;
             required, is eligible for standard surgical repair.&#xD;
&#xD;
             Angiographic Inclusion Criteria&#xD;
&#xD;
          7. Symptomatic femoropopliteal chronic total occlusions ≥ 20 cm (TASC D) that can include&#xD;
             de novo, restenotic, or in-stent restenotic lesions; or Symptomatic femoropopliteal&#xD;
             lesions ≥ 24 cm (total lesion length) that can include a chronic total occlusion or a&#xD;
             ≥70% lesion that includes de novo, restenotic or in-stent restenosis (complex TASC C),&#xD;
             by investigator visual assessment.&#xD;
&#xD;
          8. Reference vessel diameter ≥ 4.5 and ≤ 6.7 mm, by investigator visual assessment.&#xD;
&#xD;
          9. Subject has a patent popliteal artery (&lt;50% stenosis) distal to the landing zone&#xD;
&#xD;
         10. Able to successfully access the SFA origin for entry of the crossing device.&#xD;
&#xD;
         11. At least one patent infrapopliteal vessel (&lt;50% stenosis) with run-off to the ankle or&#xD;
             foot.&#xD;
&#xD;
         12. A significant stenosis (≥ 50%) or occlusion of an ipsilateral, inflow artery (e.g.&#xD;
             aortoiliac, common femoral) must be successfully treated (use of investigational&#xD;
             treatment prohibited) prior to treatment of the target lesion. Successful treatment is&#xD;
             defined as no complications and less than 30% residual stenosis following&#xD;
             intervention.&#xD;
&#xD;
        General Exclusion Criteria&#xD;
&#xD;
          1. Participating in another investigational clinical study.&#xD;
&#xD;
          2. Anticipated life expectancy less than 1 year or medical comorbid condition(s) that&#xD;
             could limit the subject's ability to comply with the requirements of the trial.&#xD;
&#xD;
          3. Subject has other medical, social or psychological problems that, in the opinion of&#xD;
             the investigator, preclude them from receiving this treatment, and the procedures and&#xD;
             evaluations pre- and post-treatment.&#xD;
&#xD;
             Clinical Exclusion Criteria&#xD;
&#xD;
          4. History of deep vein thrombosis on either limb.&#xD;
&#xD;
          5. Thrombophlebitis, within the previous 30 days.&#xD;
&#xD;
          6. 6. Planned major amputation of the target limb, including minor amputation (above the&#xD;
             ankle).&#xD;
&#xD;
          7. Prior distal amputation (above the transmetatarsal) of the target limb.&#xD;
&#xD;
          8. Known or suspected active infection at the time of the procedure (e.g., WIfI foot&#xD;
             infection grade 3: Severe infection. Local infection with systemic inflammatory&#xD;
             response syndrome [SIRS])&#xD;
&#xD;
          9. Rutherford clinical category 0, 1, 2 or 6.&#xD;
&#xD;
         10. Has acute or chronic renal disease with GFR ≤ 30 ml/min per 1.73 m2 and/or elevated&#xD;
             serum creatinine &gt;2.5mg/dL (220µmol/L) or on dialysis.&#xD;
&#xD;
         11. Known hypersensitivity/allergy to the investigational devices and/or required&#xD;
             pharmacotherapy that cannot be safely managed.&#xD;
&#xD;
         12. Morbid obesity that does not allow for safe vascular access or imaging.&#xD;
&#xD;
         13. Subject has a known coagulopathy or has bleeding diatheses, thrombocytopenia with&#xD;
             platelet count less than 100,000/microliter or INR &gt; 1.8.&#xD;
&#xD;
         14. Requires coronary or peripheral procedure within 30 days prior to or planned within 30&#xD;
             days post treatment of the target lesion.&#xD;
&#xD;
         15. Has a known history of intracranial bleeding or aneurysm, myocardial infarction or&#xD;
             stroke within the last 3 months.&#xD;
&#xD;
         16. Subject is pregnant or breast-feeding. Angiographic Exclusion Criteria&#xD;
&#xD;
         17. Stent within 3 cm of SFA ostium.&#xD;
&#xD;
         18. Previous bypass surgery on the target limb.&#xD;
&#xD;
         19. Subject has significant disease or obstruction (≥50%) of the inflow tract that has not&#xD;
             been successfully treated at the time of the index procedure (success measured as ≤30%&#xD;
             residual stenosis, without complication)&#xD;
&#xD;
         20. Presence of aneurysm or acute thrombus in the target limb.&#xD;
&#xD;
         21. Thrombolysis of the target vessel within 72 hours prior to the index procedure, where&#xD;
             complete resolution of the thrombus was not achieved.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jihad Mustapha, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Advanced Cardiac and Vascular Amputation Prevention Centers</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sean Lyden, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>HonorHealth</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85251</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Bernard's Medical Center</name>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <zip>72401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arkansas Heart Hospital</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bay Area Vein and Vascular</name>
      <address>
        <city>Burlingame</city>
        <state>California</state>
        <zip>94010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Hospital of the Monterrey Peninsula</name>
      <address>
        <city>Monterey</city>
        <state>California</state>
        <zip>93940</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Cardiovascular Specialists</name>
      <address>
        <city>Mountain View</city>
        <state>California</state>
        <zip>94040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain VA Medical Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Vascular Experts</name>
      <address>
        <city>Darien</city>
        <state>Connecticut</state>
        <zip>06820</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Coast Cardiovascular Institute</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Hospital Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christie Clinic</name>
      <address>
        <city>Champaign</city>
        <state>Illinois</state>
        <zip>61822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AMITA Health Alexian Brothers Medical Center</name>
      <address>
        <city>Elk Grove Village</city>
        <state>Illinois</state>
        <zip>60007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prairie Education and Research Cooperative</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedStar Health Research Institute</name>
      <address>
        <city>Hyattsville</city>
        <state>Maryland</state>
        <zip>20782</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McLaren Bay Region Hospital</name>
      <address>
        <city>Bay City</city>
        <state>Michigan</state>
        <zip>48708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McLaren Flint Hospital</name>
      <address>
        <city>Flint</city>
        <state>Michigan</state>
        <zip>48632</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Cardiac and Vascular Amputation Prevention Centers</name>
      <address>
        <city>Grandville</city>
        <state>Michigan</state>
        <zip>49418</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiac &amp; Vascular Research Center of Nothern Michigan</name>
      <address>
        <city>Petoskey</city>
        <state>Michigan</state>
        <zip>49770</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiology Associates of North Mississippi</name>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <zip>38801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Mexico Heart Institute</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York-Presbyterian / Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Caroline Hearth and Vascular- University of North Carolina Rex</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Christ Hospital - The Carl &amp; Edyth Lindner Center for Research &amp; Education</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinical Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miriam Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greenville Health System</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Dallas Research Associates</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Tech</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sentara Norfolk General Hospital</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aurora Research Institute</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Hochsauerland GmbH</name>
      <address>
        <city>Arnsberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardioangiologisches Centrum Bethanien</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universität Leipzig</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pauls Stradins Clinical University Hospital</name>
      <address>
        <city>Riga</city>
        <zip>1002</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Latvia</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Poland</country>
  </removed_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 11, 2017</study_first_submitted>
  <study_first_submitted_qc>April 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 18, 2017</study_first_posted>
  <last_update_submitted>May 19, 2021</last_update_submitted>
  <last_update_submitted_qc>May 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

